ALR Technologies SG Ltd.

What they do

The company, through its subsidiaries ALR Nevada and ALR Canada, develops and aims to commercialize products for chronic disease management, though specific product details are not provided in the excerpts. It operates as a development-stage entity with minimal revenue, reporting only $25,536 in annual revenue for 2023. The company has not yet achieved profitability and relies on external funding to support its operations.

Revenue drivers

• Product sales (undisclosed) — Reported annual revenue was $7,468 (2021), $2,367 (2022), and $25,536 (2023), indicating negligible product sales; no segment or product line breakdown is provided in the filing.

Recent performance

For fiscal year 2025, the company reported a net loss of $22.1 million, widening from $15.9 million in 2024, with diluted EPS of -$0.04. Operating cash flow was -$1.9 million in 2025, slightly worse than -$1.5 million in 2024. As of December 31, 2025, total assets were $47,374, total liabilities $39.9 million, and shareholder equity was negative at -$39.9 million. Revenue figures beyond 2023 were not provided, but the company remains in a development stage with minimal commercial activity.

Strategy

Management is reviewing strategic options, as noted in risk factors, and the company is dependent on additional capital to continue product development. The company relies on third parties for nonclinical and clinical trials and on single-source suppliers, indicating an outsourcing approach to development. They also depend on strategic relationships and potential joint ventures or mergers and acquisitions. No specific product pipeline details were disclosed in the provided excerpts.

Risks

• Development-stage losses — The company has a history of operating losses and limited commercial history, with net losses consistently above $7 million annually since 2021.
• Funding dependency — Substantial additional funding is required to continue development, and there is a possibility the company cannot raise capital when needed.
• Regulatory approval uncertainty — Product candidates may not receive regulatory approval, and if approved, face ongoing regulatory obligations and potential reimbursement hurdles.
• Negative equity — Shareholder equity was -$39.9 million as of December 31, 2025, indicating accumulated deficits and potential solvency concerns.

Outlook

Management has not provided specific forward-looking guidance in the excerpts, but the company continues to operate as a development-stage entity with expectations of additional losses and capital needs. The outcome of the strategic options review could materially affect future operations. No timeline for commercialization or profitability was disclosed.